Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Arena Pharmaceutical (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,706,521
  • Shares Outstanding, K 49,570
  • Annual Sales, $ 17,970 K
  • Annual Income, $ -29,400 K
  • 60-Month Beta 1.75
  • Price/Sales 147.58
  • Price/Cash Flow N/A
  • Price/Book 2.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.02
  • Number of Estimates 3
  • High Estimate -0.77
  • Low Estimate -1.16
  • Prior Year -0.65
  • Growth Rate Est. (year over year) -56.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.83 +25.94%
on 04/23/19
58.00 -4.83%
on 05/16/19
+10.72 (+24.10%)
since 04/22/19
3-Month
42.48 +29.94%
on 04/18/19
58.00 -4.83%
on 05/16/19
+4.93 (+9.81%)
since 02/22/19
52-Week
31.97 +72.66%
on 11/14/18
58.00 -4.83%
on 05/16/19
+9.00 (+19.48%)
since 05/22/18

Most Recent Stories

More News
First Week of ARNA August 16th Options Trading

Investors in Arena Pharmaceuticals Inc saw new options begin trading this week, for the August 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay,...

ARNA : 54.65 (+0.09%)
Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate etrasimod 2 mg in subjects with moderately to severely active...

ARNA : 54.65 (+0.09%)
Notable Thursday Option Activity: ARNA, BG, KNX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arena Pharmaceuticals Inc , where a total of 3,143 contracts have traded so far, representing...

ARNA : 54.65 (+0.09%)
All You Need to Know About Arena Pharmaceuticals (ARNA) Rating Upgrade to Buy

Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ARNA : 54.65 (+0.09%)
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences:

ARNA : 54.65 (+0.09%)
Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up

Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.

ARNA : 54.65 (+0.09%)
CLSN : 2.05 (-3.76%)
FCSC : 1.99 (+3.65%)
UTHR : 86.57 (-2.46%)
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2019.

ARNA : 54.65 (+0.09%)
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.

LLY : 116.81 (+0.20%)
ARNA : 54.65 (+0.09%)
MNKD : 1.28 (-1.54%)
UTHR : 86.57 (-2.46%)
Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 18th Annual Needham Healthcare...

ARNA : 54.65 (+0.09%)
New Research Coverage Highlights The Blackstone Group, Arena Pharmaceuticals, Arrow Electronics, AdvanSix, KBR, and RPM International -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of The Blackstone Group L.P....

BX : 41.97 (+0.41%)
ARW : 67.97 (-0.28%)
ARNA : 54.65 (+0.09%)
KBR : 21.98 (-1.26%)
RPM : 55.31 (-0.43%)
ASIX : 27.73 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARNA with:

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

2nd Resistance Point 55.72
1st Resistance Point 55.16
Last Price 54.65
1st Support Level 53.63
2nd Support Level 52.66

See More

52-Week High 58.00
Last Price 54.65
Fibonacci 61.8% 48.06
Fibonacci 50% 44.99
Fibonacci 38.2% 41.91
52-Week Low 31.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar